New trial aims to find best first treatment for High-Risk lung disease patients
NCT ID NCT07245680
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study compares starting with two oral medications (tadalafil and ambrisentan) versus just one in people newly diagnosed with pulmonary arterial hypertension who also have at least two heart-related conditions. The goal is to see which approach better lowers risk and improves outcomes after 24 weeks. About 186 participants will be enrolled across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION PAH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Bicêtre -Service de pneumologie et soins intensifs respiratoires
RECRUITINGLe Kremlin-Bicêtre, 94270, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.